Last updated on April 2020

Clarity AD - Mild Cognitive Impairment / Early Alzheimer’s Disease Research Study


Brief description of study

The Memory Health Center at Summit Research Network, is enrolling participants in the Clarity AD Research Study.  This research study will evaluate whether an investigational study drug is safe and effective in slowing the progression of Alzheimer’s.

Study participation may last to up 23 months with the option to participate in an extension for another 24 months. Following a screening period of up to 2 months, qualified participants will be randomly assigned to receive either the intravenous investigational study drug, , or a placebo (an inactive substance) and enter into an 18 month treatment period.  During the treatment period, the participants will visit the research center every 2 weeks to receive the study drug or placebo. 

Additional memory and safety assessments will be completed during the visits at specified time points throughout the study. 

At the end of the 18 month treatment period, those entering the optional open-label study extension, will receive the investigational study drug, and visit the study center every 2 weeks for the study visit. Participants who do not enter the open label study extension, will attend a follow-up visit 3 months after their final study visit.

 

Clinical Study Identifier: TX235494

Find a site near you

Start Over

Summit Research Network, Inc.

2701 NW Vaughn Street, Suite 350 Portland, OR USA
  Connect »